This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Ibuprofen and Famotidine

Read time: 1 mins
Marketing start date: 12 Jul 2025
...
 

Summary of product characteristics


Effective Time

20250528

Version

1

Spl Product Data Elements

Ibuprofen and Famotidine Ibuprofen and Famotidine IBUPROFEN IBUPROFEN FAMOTIDINE FAMOTIDINE CROSCARMELLOSE SODIUM FERROSOFERRIC OXIDE GLYCERYL MONO- AND DICAPRYLOCAPRATE HYPROMELLOSE 2910 (15 MPA.S) MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE POLYVINYL ALCOHOL, UNSPECIFIED PROPYLENE GLYCOL SHELLAC SILICON DIOXIDE SODIUM LAURYL SULFATE TALC TITANIUM DIOXIDE White to off-white 777

Application Number

ANDA218684

Brand Name

Ibuprofen and Famotidine

Generic Name

Ibuprofen and Famotidine

Product Ndc

70771-1924

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Ibuprofen and famotidine tablets, 800 mg/26.6 mg 90 Tablets NDC 70771-1924-9 Rx only image

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.